

Table SIII. Psoriasis disease severity measured with the Psoriasis Area Severity Index (PASI), the Dermatology Life Quality Index (DLQI) and the Visual Analogue Scale (VAS) for the psoriasis group at baseline and after 24 weeks of treatment with etanercept. Comparison between the two groups at baseline (*p*-value; difference between groups at baseline) regarding the studied biochemical variables as well as changes in these variables within each group (*p*-value for trend in time) during the 24-week period

	Patients with psoriasis, <i>n</i> = 20							Healthy controls, <i>n</i> = 15							<i>p</i> -value; difference at baseline between groups ^b
	Min	Median	Max	Mean	SD	<i>n</i>	<i>p</i> -value for trend in time ^a	Min	Median	Max	Mean	SD	<i>n</i>	<i>p</i> -value for trend in time ^a	
PASI score															
Baseline	7	11	28	13	5	20	<0.0001								
24 weeks	0	2	12	3	3	17									
DLQI															
Baseline	0	12	26	13	7	14	0.0016								
24 weeks	0	0	11	2	4	11									
VAS															
Baseline	0	8	10	7	3	20	<0.0001								
24 weeks	0	1	9	2	3	11									
hsCRP (µg/ml)															
Baseline	0	4	14	4	4	20	0.011	0.3	1.0	9.7	2.0	2.4	15	0.55	0.010
24 weeks	0	2	7	2	2	17		0.3	1.4	5.6	1.9	1.6	12		
DBP (µg/ml)															
Baseline	165	225	478	234	63	20	0.003	175.0	218.0	258.0	221.8	23.5	15	0.083	0.70
24 weeks	122	211	273	202	39	17		181.0	224.0	251.0	222.2	19.2	12		
25(OH)D (nmol/l)															
Baseline	43	66	186	74	31	20	0.34	28	50	87	53	19	14	0.029	0.018
24 weeks	43	77	122	76	23	17		42	74	106	73	20	12		
Free 25(OH)D (pmol/l)															
Baseline	7.5	11.1	26.2	11.8	4.0	20	0.84	4.5	7.2	12.0	8.0	2.6	15	0.006	0.0014
24 weeks	7.7	11.0	19.2	11.7	2.8	17		7.0	10.1	16.5	10.2	2.9	12		
Calculated free 25(OH)D (pmol/l)															
Baseline	13	23	63	24	11	20	0.030	11	15	26	17	6	14	0.013	0.018
24 weeks	16	26	45	27	9	17		14	25	37	24	6	12		
Percentage of free 25(OH)D (%)															
Baseline	0.011	0.017	0.022	0.016	0.003	20	0.67	0.011	0.015	0.022	0.016	0.003	14	0.22	0.23
24 weeks	0.011	0.016	0.025	0.016	0.004	17		0.012	0.013	0.017	0.014	0.002	12		
1,25(OH)2D (pmol/l)															
Baseline	44	90	161	103	34	20	0.68	38	93	146	91	36	15	0.088	0.33
24 weeks	54	96	128	96	20	17		51	115	161	112	38	12		
PTH (pmol/l)															
Baseline	1.8	3.2	7.8	3.8	1.7	20	0.027	2.4	3.8	8.6	4.1	1.6	14	0.53	0.29
24 weeks	1.5	3.9	10.5	4.5	2.8	17		1.8	3.6	6.8	3.4	1.4	12		
Albumin (g/l)															
Baseline	35	40	47	40	2.5	20	0.47	38	42	48	42	2.6	15	0.69	0.007
24 weeks	35	41	45	40	2.8	17		38	43	47	42	2.5	12		
Calcium (mmol/l)															
Baseline	2.26	2.39	2.62	2.41	0.10	20	0.11	2.23	2.44	2.59	2.44	0.10	15	0.62	0.35
24 weeks	2.25	2.34	2.52	2.38	0.10	17		2.40	2.42	2.49	2.43	0.03	12		
Creatinine (µmol/l)															
Baseline	55	78	114	78	15	20	0.024	59.0	88.0	104	84	14	15	0.40	0.22
24 weeks	58	83	110	82	13	17		65.0	88.0	108	87	12	12		
ALP (µkat/l)															
Baseline	0.7	1.2	2.9	1.3	0.5	20	0.025	0.9	1.1	1.8	1.3	0.3	15	0.30	0.72
24 weeks	0.8	1.2	2.7	1.3	0.5	17		0.9	1.2	1.9	1.3	0.3	12		

^aSpearman's test, stratifying with respect to patient. ^bWilcoxon rank sum test.
DBP: vitamin D-binding protein; PTH: parathyroid hormone; ALP: alkaline phosphatase.